FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981677796> ?p ?o ?g. }

• W2981677796 abstract "Benefited from the continuously clarifying underlying biology of immune checkpoints and ligands-receptors interactions, the emergence of new anti-cancer treatment strategy -- immunotherapy has showed substantial benefits on several liquid and solid tumors. Immune checkpoint inhibitors (ICIs) can block the negative regulatory components and enhance the T-cell function, thus let to prominent anti-cancer activity. On account of its promising effect on various malignancies that showed in the clinical trials, ICIs have been considered to be the most potent anti-cancer agents in the near future. Head and neck cancer is the 7th common neoplasm worldwide and the gross 5-year survival rate was only 60%. Managing locoregionally advanced, recurrent or metastatic head and neck tumors were still the challenging problems for both oncologists and surgeons. Recent clinical trials employing the immune-modulating antibodies that target cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) herald a new era of anti-cancer therapy. However, like all other anti-cancer drugs, ICIs also have side effects while upregulating the immune system to enhance antitumor response, which was known as immune-related adverse events (irAEs). Generally, most irAEs were transient, but sometimes they can cause serious organ dysfunction, even fatal. In addition, due to the distinct anatomical feature, advanced head and neck tumors often affect the upper aerodigestive track and cause serious dyspnea or dysphagia. Toxicities of ICIs may more lethal for such patients. Thus, as the increasing application of anti-checkpoint agents in head and neck cancer, there is urgent need to ascertain the safety of this novel treatment strategy. Here we compile this review of existing clinical trials on toxicity of ICIs during cancer treatment. The particular clinical manifestation, characteristics of complication development in fatal cases and the management strategies were discussed. This may provide vital information for future oncology trials and clinical practice." @default.
• W2981677796 created "2019-11-01" @default.
• W2981677796 creator A5013052976 @default.
• W2981677796 creator A5014590049 @default.
• W2981677796 creator A5015948049 @default.
• W2981677796 creator A5029195269 @default.
• W2981677796 creator A5055078355 @default.
• W2981677796 creator A5070216134 @default.
• W2981677796 creator A5077702516 @default.
• W2981677796 date "2019-10-23" @default.
• W2981677796 modified "2023-10-17" @default.
• W2981677796 title "Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management" @default.
• W2981677796 cites W2046540943 @default.
• W2981677796 cites W2163814058 @default.
• W2981677796 cites W2198093519 @default.
• W2981677796 cites W2259730793 @default.
• W2981677796 cites W2401455386 @default.
• W2981677796 cites W2523194272 @default.
• W2981677796 cites W2560367415 @default.
• W2981677796 cites W2572174216 @default.
• W2981677796 cites W2600848170 @default.
• W2981677796 cites W2602907503 @default.
• W2981677796 cites W2607817468 @default.
• W2981677796 cites W2607929283 @default.
• W2981677796 cites W2610480623 @default.
• W2981677796 cites W2620740965 @default.
• W2981677796 cites W2736166064 @default.
• W2981677796 cites W2747016053 @default.
• W2981677796 cites W2766233251 @default.
• W2981677796 cites W2768429453 @default.
• W2981677796 cites W2771267201 @default.
• W2981677796 cites W2786816161 @default.
• W2981677796 cites W2790502904 @default.
• W2981677796 cites W2791483720 @default.
• W2981677796 cites W2792375558 @default.
• W2981677796 cites W2794577178 @default.
• W2981677796 cites W2799372507 @default.
• W2981677796 cites W2810680591 @default.
• W2981677796 cites W2891486030 @default.
• W2981677796 cites W2893321040 @default.
• W2981677796 cites W2898092643 @default.
• W2981677796 cites W2898717093 @default.
• W2981677796 cites W2902856530 @default.
• W2981677796 cites W2903072703 @default.
• W2981677796 cites W2903493423 @default.
• W2981677796 cites W2905201605 @default.
• W2981677796 cites W2909370899 @default.
• W2981677796 cites W2910047340 @default.
• W2981677796 cites W2911762019 @default.
• W2981677796 cites W2911897655 @default.
• W2981677796 cites W2913384100 @default.
• W2981677796 cites W2917837889 @default.
• W2981677796 cites W2943668434 @default.
• W2981677796 cites W2945637375 @default.
• W2981677796 doi "https://doi.org/10.3389/fphar.2019.01254" @default.
• W2981677796 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6819434" @default.
• W2981677796 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31708780" @default.
• W2981677796 hasPublicationYear "2019" @default.
• W2981677796 type Work @default.
• W2981677796 sameAs 2981677796 @default.
• W2981677796 citedByCount "19" @default.
• W2981677796 countsByYear W29816777962020 @default.
• W2981677796 countsByYear W29816777962021 @default.
• W2981677796 countsByYear W29816777962022 @default.
• W2981677796 countsByYear W29816777962023 @default.
• W2981677796 crossrefType "journal-article" @default.
• W2981677796 hasAuthorship W2981677796A5013052976 @default.
• W2981677796 hasAuthorship W2981677796A5014590049 @default.
• W2981677796 hasAuthorship W2981677796A5015948049 @default.
• W2981677796 hasAuthorship W2981677796A5029195269 @default.
• W2981677796 hasAuthorship W2981677796A5055078355 @default.
• W2981677796 hasAuthorship W2981677796A5070216134 @default.
• W2981677796 hasAuthorship W2981677796A5077702516 @default.
• W2981677796 hasBestOaLocation W29816777961 @default.
• W2981677796 hasConcept C121608353 @default.
• W2981677796 hasConcept C126322002 @default.
• W2981677796 hasConcept C143998085 @default.
• W2981677796 hasConcept C197934379 @default.
• W2981677796 hasConcept C203014093 @default.
• W2981677796 hasConcept C2776530083 @default.
• W2981677796 hasConcept C2777701055 @default.
• W2981677796 hasConcept C2780674031 @default.
• W2981677796 hasConcept C2780851360 @default.
• W2981677796 hasConcept C535046627 @default.
• W2981677796 hasConcept C71924100 @default.
• W2981677796 hasConcept C8891405 @default.
• W2981677796 hasConceptScore W2981677796C121608353 @default.
• W2981677796 hasConceptScore W2981677796C126322002 @default.
• W2981677796 hasConceptScore W2981677796C143998085 @default.
• W2981677796 hasConceptScore W2981677796C197934379 @default.
• W2981677796 hasConceptScore W2981677796C203014093 @default.
• W2981677796 hasConceptScore W2981677796C2776530083 @default.
• W2981677796 hasConceptScore W2981677796C2777701055 @default.
• W2981677796 hasConceptScore W2981677796C2780674031 @default.
• W2981677796 hasConceptScore W2981677796C2780851360 @default.
• W2981677796 hasConceptScore W2981677796C535046627 @default.
• W2981677796 hasConceptScore W2981677796C71924100 @default.
• W2981677796 hasConceptScore W2981677796C8891405 @default.
• W2981677796 hasLocation W29816777961 @default.
• W2981677796 hasLocation W29816777962 @default.

• next